#Pfizer has claimed #FDA approval for front-line maintenance use of its oral #HER2inhibitor #Tukysa in #breastcancer, an indication it hopes will unlock the product's growth potential.
@pharmaphorum.bsky.social
@pharmaphorum.bsky.social
@pharmaphorum.bsky.social#Pfizer has claimed #FDA approval for front-line maintenance use of its oral #HER2inhibitor #Tukysa in #breastcancer, an indication it hopes will unlock the product's growth potential.